Regarding the important role of PD-L1 expression by tumor cells, as described above, several studies have seen no or variable changes in PD-L1 expression in various cancer cell lines upon administration of MEKi, dependent on specific cell line, experimental context or duration of MEK inhibition (13, 183). The gene discussed is MAP2K7; the disease is cancer.